Jim E. Eyles

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.

Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.

Journal: Oncoimmunology
Published: June 05, 2026

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

Journal: Journal for immunotherapy of cancer
Published: July 07, 2025

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses.

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses.

Journal: Research square
Published: May 05, 2025

Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models.

Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models.

Journal: Journal for immunotherapy of cancer
Published: April 21, 2025

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses.

Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses.

Journal: Cancer immunology, immunotherapy : CII
Published: February 13, 2025

Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models.

Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models.

Journal: Cancers
Published: November 20, 2024

Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models.

Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models.

Journal: Science translational medicine
Published: October 30, 2024

A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selection.

A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selection.

Journal: CPT: pharmacometrics & systems pharmacology
Published: February 17, 2024

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

Journal: Cancer biology & therapy
Published: January 11, 2024

CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells.

CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells.

Journal: Science advances
Published: October 18, 2023

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.

Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.

Journal: Journal for immunotherapy of cancer
Published: July 16, 2023

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.

Journal: Journal for immunotherapy of cancer
Published: April 17, 2023
Showing 1-12 of 17

Last Updated: 09/26/2026